"Novartis’s copy of Betaseron is called Extavia. It’s the exact same drug, with a different name. Novartis got the rights to launch a copy of Betaseron through a complicated deal stemming from its 2006 acquisition of Chiron. Novartis has already started selling Extavia in Europe, and is paying Bayer royalties on the sales.
Both Betaseron and Extavia are known by the generic name interferon beta-1b. Interferon beta-1b is a widely used injectible drug, prescribed to reduce the frequency of clinical exacerbations in relapsing forms of MS."